Skip to content

Category: Science Medical

France Expands National AAC Access for Agenus’ Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

By API User

Updated national AAC protocol supports hospital-based, fully-reimbursed compassionate access across three solid tumor settings LEXINGTON, Mass.–BUSINESS WIRE– Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that France’s National Agency for Medicines and Health Products Safety (ANSM) has approved an updated national treatment protocol for botensilimab (BOT) plus balstilimab (BAL) under France’s Autorisation … Continued

Long-acting HIV PrEP registration brings us another step closer to ending HIV for Australia, but access remains a barrier

By API User

Long-acting HIV PrEP registration brings us another step closer to ending HIV for Australia, but access remains a barrier   Health Equity Matters has welcomed the registration of the long-acting PrEP option Lencapavir by Australia’s Therapeutic Goods Administration, with the drug having the potential to significantly bolster HIV prevention in Australia.   Lencapavir is the … Continued

Comparative Analysis Highlights Potential Benefits of OncoSilTM Therapy

By API User

Sydney, Australia – 12 January 2026: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce the publication of a peer-reviewed study in Gastrointestinal Endoscopy titled: “Combined phosphorus-32 implantation and chemotherapy versus chemotherapy alone … Continued

Building on bulk billing impacts can make primary health care nurses even more effective

By API User

The Australian Primary Health Care Nurses Association (APNA) has today welcomed news that bulk billing incentives are improving access to primary health care.   “As primary health care nurses, we’re passionate about health equity, and making sure that people can get affordable and equitable access to primary health care” said APNA President Denise Lyons.   “The government’s bulk billing incentives are important in supporting people to access the care … Continued

PromiCell, Inc. presents during JP Morgan’s 2026 Healthcare Conference

By API User

MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company’s Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company’s lead asset PRO CAR – 201A, … Continued

Bruder Consulting & Venture Group to become Dark Horse Consulting Regenerative Medicine

By API User

WALNUT CREEK, Calif. and NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) — Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, is pleased to announce the acquisition of Bruder Consulting & Venture Group (“Bruder” or “BCVG”), a strategic advisory and consulting firm with a global footprint in biotech … Continued

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)

By API User

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs   BEIJING & ALAMEDA, Calif. & TAIPEI–BUSINESS WIRE– Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to … Continued

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

By API User

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies GHENT, Belgium–BUSINESS WIRE– MRM Health NV, … Continued

Australian scientists solve enduring mystery about diseases driven by uncontrolled cell growth, including cancer and epilepsy

By API User

For the first time, scientists have answered a longstanding question in cell biology about a partnership of proteins called the “KICSTOR–GATOR1 complex” which operate as a control system inside our cells, telling them when to grow and when to stop based on nutrient availability (especially amino acids). The Monash University study, published in the prestigious … Continued

GPs commend training boost and equitable ECG funding

By API User

The Australian Government will invest $14.5 million for an extra 306 places in the fully Commonwealth-funded Australian GP Training (AGPT) Program, having previously announced 200 more places in the program in 2026, a move the Royal Australian College of GPs (RACGP) has called a win for access to GPs. Patients will also receive the same … Continued